These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 26035328)

  • 41. Efficacy of raltegravir-containing regimens in antiretroviral-naïve and -experienced individuals in routine clinical practice.
    Jaeckle M; Khaykin P; Haberl A; De Leuw P; Schüttfort G; Stephan C; Wolf T
    Int J STD AIDS; 2016 Nov; 27(13):1170-1179. PubMed ID: 26429890
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of antiretroviral regimens including raltegravir to treat HIV-infected patients with hemophilia.
    Xiao H; Xue Y; Gu S; Wang J; Sun H; Lu H
    Biosci Trends; 2016 Feb; 10(1):42-6. PubMed ID: 26911541
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing.
    Armenia D; Vandenbroucke I; Fabeni L; Van Marck H; Cento V; D'Arrigo R; Van Wesenbeeck L; Scopelliti F; Micheli V; Bruzzone B; Lo Caputo S; Aerssens J; Rizzardini G; Tozzi V; Narciso P; Antinori A; Stuyver L; Perno CF; Ceccherini-Silberstein F
    J Infect Dis; 2012 Feb; 205(4):557-67. PubMed ID: 22238474
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Five years' real-life experience with raltegravir in a large HIV centre.
    van Halsema C; Whitfield T; Lin N; Ashton K; Torkington A; Ustianowski A
    Int J STD AIDS; 2016 Apr; 27(5):387-93. PubMed ID: 25931236
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High frequency of dolutegravir resistance in patients failing a raltegravir-containing salvage regimen.
    Cavalcanti Jde S; Ferreira JL; Guimarães PM; Vidal JE; Brigido LF
    J Antimicrob Chemother; 2015 Mar; 70(3):926-9. PubMed ID: 25386009
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
    Cooper DA; Steigbigel RT; Gatell JM; Rockstroh JK; Katlama C; Yeni P; Lazzarin A; Clotet B; Kumar PN; Eron JE; Schechter M; Markowitz M; Loutfy MR; Lennox JL; Zhao J; Chen J; Ryan DM; Rhodes RR; Killar JA; Gilde LR; Strohmaier KM; Meibohm AR; Miller MD; Hazuda DJ; Nessly ML; DiNubile MJ; Isaacs RD; Teppler H; Nguyen BY;
    N Engl J Med; 2008 Jul; 359(4):355-65. PubMed ID: 18650513
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunovirological outcomes and resistance patterns at 4 years of antiretroviral therapy use in HIV-infected patients in Cambodia.
    Pujades-Rodríguez M; Schramm B; Som L; Nerrienet E; Narom P; Chanchhaya N; Ferradini L; Balkan S
    Trop Med Int Health; 2011 Feb; 16(2):205-13. PubMed ID: 21087376
    [TBL] [Abstract][Full Text] [Related]  

  • 48. No residual activity of raltegravir after development of 148 complex mutations in vivo.
    Khanlou H; Sayana S; Acosta E
    J Int Assoc Physicians AIDS Care (Chic); 2008; 7(6):281-2. PubMed ID: 19164138
    [No Abstract]   [Full Text] [Related]  

  • 49. High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali.
    Fofana DB; Soulié C; Baldé A; Lambert-Niclot S; Sylla M; Ait-Arkoub Z; Diallo F; Sangaré B; Cissé M; Maïga IA; Fourati S; Koita O; Calvez V; Marcelin AG; Maïga AI
    J Antimicrob Chemother; 2014 Sep; 69(9):2531-5. PubMed ID: 24855120
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impaired CD4+ cell recovery during antiretroviral therapy in patients with HIV resistance mutations.
    Sühs KW; Stoll M; Diem R; Schmidt RE; Heiken H
    Arch Virol; 2012 Mar; 157(3):433-40. PubMed ID: 22179846
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient.
    Boyd SD; Maldarelli F; Sereti I; Ouedraogo GL; Rehm CA; Boltz V; Shoemaker D; Pau AK
    Antivir Ther; 2011; 16(2):257-61. PubMed ID: 21447876
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Virologic outcomes of first-line HAART and associated factors among Chinese patients with HIV in three sentinel antiretroviral treatment sites.
    Ruan Y; Xing H; Wang X; Tang H; Wang Z; Liu H; Su B; Wu J; Li H; Liao L; Li J; Wu JW; Shao Y
    Trop Med Int Health; 2010 Nov; 15(11):1357-63. PubMed ID: 20868414
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
    Ghosn J; Pellegrin I; Goujard C; Deveau C; Viard JP; Galimand J; Harzic M; Tamalet C; Meyer L; Rouzioux C; Chaix ML;
    AIDS; 2006 Jan; 20(2):159-70. PubMed ID: 16511408
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Alternative switching strategies based on regimens with a low genetic barrier: do clinicians have a choice nowadays?
    Troya J; Ryan P; Montejano R; Cabello A; Cuevas G; Matarranz M; Cañamares I; Solís J; Walther LÁ
    Eur J Clin Microbiol Infect Dis; 2019 Mar; 38(3):423-426. PubMed ID: 30443683
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk factors for raltegravir resistance development in clinical practice.
    Malet I; Fourati S; Morand-Joubert L; Flandre P; Wirden M; Haim-Boukobza S; Sayon S; Pattery T; Simon A; Katlama C; Girard PM; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2012 Oct; 67(10):2494-500. PubMed ID: 22763565
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dutrebis (lamivudine and raltegravir) for use in combination with other antiretroviral products for the treatment of HIV-1 infection.
    Casado JL; Bañón S
    Expert Rev Clin Pharmacol; 2015; 8(6):709-18. PubMed ID: 26517111
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance.
    Grant PM; Zolopa AR
    Curr Opin Investig Drugs; 2010 Aug; 11(8):901-10. PubMed ID: 20721832
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients.
    Calcagno A; D'Avolio A; Bonora S
    Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1167-76. PubMed ID: 26073580
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents.
    Briz V; León-Leal JA; Palladino C; Moreno-Perez D; de Ory SJ; De José MI; González-Tomé MI; Martín CG; Pocheville I; Ramos JT; Leal M; Muñoz-Fernández MÁ
    Pediatr Infect Dis J; 2012 Mar; 31(3):273-7. PubMed ID: 22330165
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA.
    Rossetti B; Meini G; Bianco C; Lamonica S; Mondi A; Belmonti S; Fanti I; Ciccarelli N; Di Giambenedetto S; Zazzi M; De Luca A
    J Clin Virol; 2017 Jun; 91():18-24. PubMed ID: 28395180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.